A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

Completed · Phase 3 · Has a placebo group

Conditions studied: Type 2 Diabetes Mellitus

In brief

This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to determine the effect of ranolazine when added to metformin on glycemic control in adults with type 2 diabetes mellitus (T2DM) who are inadequately controlled despite current treatment with stable metformin therapy in addition to diet and exercise.

Key facts

Study ID

NCT01555164

Run by

Gilead Sciences

People needed

442

Starts

2012-06-01

Expected to finish

2013-10-01

Last updated by the study team

2014-09-23

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented history of T2DM
• Metformin therapy at a stable total daily dose ≥ 1500 mg and ≤ 2550 mg in addition to diet and exercise for ≥ 8 weeks prior to Screening
• Body mass index (BMI) 25 to 45 kg/m\^2, inclusive, at Screening
• HbA1c within specified ranges at Screening and at the end of the Qualifying Period based on current metformin dose
• C-peptide ≥ 0.8 ng/mL at Screening
• Fasting serum glucose (FSG) ≥ 130 mg/dL (7.2 mmol/L) and ≤ 240 mg/dL (13.3 mmol/L) at Screening and at the end of the Qualifying Period

You may not qualify if…

• Type 1 diabetes mellitus
• History of diabetic ketoacidosis, ketosis-prone diabetes, or hyperosmolar hyperglycemic coma
• History of severe hypoglycemia
• Any clinically significant cardiovascular or cerebrovascular event ≤ 3 months prior to Screening
• History of congestive heart failure
• Corrected QT interval (QTc) > 500 msec by ECG at Screening, a personal or family history of QTc prolongation, congenital long QT syndrome, or individuals who are receiving drugs that prolong the QTc interval, such as Class Ia or Class III antiarrhythmic agents, erythromycin, and certain antipsychotics (eg, ziprasidone)
• Serum creatinine concentration ≥ 1.5 mg/dL for males or ≥ 1.4 mg/dL for females at Screening
• Active liver disease and/or significant abnormal liver function defined as aspartate aminotransferase (AST) > 3 x upper limit of the normal range (ULN) and/or alanine aminotransferase (ALT) > 3 x ULN and/or serum total bilirubin > 2.0 mg/dL
• Use of any non-insulin antihyperglycemic therapy (other than metformin) for more than 14 days (consecutive or not) during the 12 weeks (24 weeks for thiazolidinediones) prior to Screening and/or use of any antihyperglycemic therapy other than metformin, at any dose, at any time during the 4 weeks prior to randomization
• Treatment with chronic insulin within 24 weeks prior to Screening (except for one temporary period of daily insulin injections no longer than 7 days)
• Treatment with strong or moderate cytochrome P450 3A (CYP3A) inhibitors or P-glycoprotein (P-gp) inhibitors within 14 days prior to randomization
• Treatment with CYP3A inducers or P-gp inducers within 14 days prior to randomization
• Treatment with simvastatin or lovastatin at a dose > 20 mg or > 40 mg daily, respectively, within 14 days prior to randomization

Where it is running

• KLR Business Group DBA Arkansas Clinical Research — Little Rock, Alaska, United States
• Radiant Research, Inc. — Chandler, Arizona, United States
• Central Phoenix Medical Clinic — Phoenix, Arizona, United States
• Clinical Research Advantage — Tempe, Arizona, United States
• Desert Sun Clinical Research, LLC — Tucson, Arizona, United States
• National Research Institute — Los Angeles, California, United States
• Ritchken and First MD's — San Diego, California, United States
• Clearview Medical Research, LLC — Santa Clarita, California, United States
• Metabolic Institute of America — Tarzana, California, United States
• University Clinical Investigators — Tustin, California, United States
• Infosphere Clinical Research — West Hills, California, United States
• Colorado Springs Health Partners — Colorado Springs, Colorado, United States
• Boca Raton Clinical Research Associates, Inc. — Boca Raton, Florida, United States
• MD Clinical Institute — Hallandale, Florida, United States
• A G A Clinical Trials — Hialeah, Florida, United States
• Baptist Diabetes Associates — Miami, Florida, United States
• Florida Institute for Clinical Research LLC — Orlando, Florida, United States
• Medical Research Group of Central Florida — Sanford, Florida, United States
• Synergy Therapeutic Partners — Atlanta, Georgia, United States
• Perimeter Institute for Clinical Research — Atlanta, Georgia, United States
• Columbus Research Foundation — Columbus, Georgia, United States
• Advanced Clinical Research — Boise, Idaho, United States
• Choose To Lose — Eagle, Idaho, United States
• Cedar-Crosse Research Center — Chicago, Illinois, United States
• Fundamental Research LLC — Gulf Shores, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.